Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Abbott (NYSE: ABT) presented data at ESMO 2026 showing its Oncodetect® test improved sensitivity for detecting colorectal cancer recurrence by 30% compared to its previous test. The study found a 10.6-fold higher recurrence risk for patients with detectable ctDNA. Abbott aims to connect innovations across cancer care, from early detection to post-treatment monitoring.
How this was made
The 30-second read
Why it matters
The 30% sensitivity boost could expand Abbott's market share in liquid biopsy diagnostics and support higher pricing or volume.
Market read
First-time release of significant clinical data for Abbott's MRD test, potentially influencing stock valuation and sector dynamics.
What to watch
The test is not FDA-approved yet; adoption depends on payer acceptance and competition from other MRD platforms.
Background
Abbott's Oncodetect MRD test aims to detect residual disease post-surgery using whole-genome sequencing, building on its Cologuard colorectal screening product.
Ticker impact
Abbott announced new Beta-CORRECT data showing a 30% absolute improvement in sensitivity for its WGS Oncodetect MRD test in colorectal cancer.
likely upward pressure as investors price in improved test performance and potential market expansion.
First disclosure of significant sensitivity gain; no prior public data; could drive revenue expectations for the diagnostics business.
Market effects
Strengthens the broader molecular diagnostics and liquid biopsy sector, potentially benefiting peers with similar MRD offerings.
May lift US healthcare and biotech stocks as investors reassess diagnostic pipelines.
Highlights the growing importance of ctDNA testing worldwide, could influence global diagnostic adoption.
Counterpoint
If reimbursement or regulatory clearance stalls, the data may not translate into commercial upside.
Key entities
- CompanyAbbott Laboratories
US healthcare company presenting new MRD test data.
- InstitutionNational Cancer Center Hospital East
Japanese hospital collaborating on the Beta-CORRECT study.
